Cog­nate dou­bles man­u­fac­tur­ing ca­pac­i­ties in Mem­phis, Eu­rope, as de­mand for cell and gene ther­a­pies sky­rock­ets

The mar­ket­place for gene and cell man­u­fac­tur­ing ther­a­peu­tics con­tin­ues to be scorch­ing.

Cog­nate Bio­Sciences, a lead­ing CD­MO spe­cial­iz­ing in gene and cell ther­a­py tech­nolo­gies, an­nounced plans Fri­day that will dou­ble its to­tal man­u­fac­tur­ing ca­pac­i­ties at sites in both the US and Eu­rope — in di­rect re­sponse to a “great de­mand of com­mer­cial ca­pac­i­ty with­in the bi­o­log­ics in­dus­try.”

The com­pa­ny pro­vid­ed most de­tails for its US ex­pan­sion, which will take place at its cur­rent head­quar­ters in Mem­phis, Ten­nessee near the Mem­phis In­ter­na­tion­al Air­port — cru­cial, it said, as Mem­phis is one of the world’s busiest car­go air­ports. Cog­nate will add two sep­a­rate fa­cil­i­ties to­tal­ing 250,000-square-feet: a GMP dis­tri­b­u­tion cen­ter to man­age glob­al sup­ply chain needs, and a third site for com­mer­cial man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER